+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States



Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States



Aids Patient Care and Stds 24(5): 279-286



This retrospective cohort study of HIV-infected women receiving highly active antiretroviral therapy (HAART) while pregnant assessed the effect of postpartum HAART discontinuation on maternal AIDS-defining events (ADEs), non-AIDS-defining events (non-ADEs), and death 1997-2008 in Nashville, Tennessee. Cox proportional hazards models compared rates of ADE or all-cause death and non-ADE or all-cause death, and competing risks analyses compared rates of ADE or ADE-related death and non-ADE or non-ADE-related death across the groups. There were two groups: women who stopped HAART postpartum (discontinuation, n = 54) and women who continued HAART postpartum (continuation, n = 69). Fifty percent were African American, 40% had prior non-HAART antiretroviral therapy (ART) use, and 38% had a history of illicit drug use. Median age was 27.5 years, baseline CD4(%) was 532 (34%) and CD4 nadir was 332 cells/mm(3), baseline and peak HIV-1 RNA were 2.6 and 4.32 log(10) copies per milliliter, respectively. Women in the continuation group were older, had lower baseline CD4, CD4%, and CD4 nadir, and had higher peak HIV-1 RNA. In multivariable proportional hazards models, the hazard ratios [95% confidence interval (CI)] of ADE or all-cause death and non-ADE or all-cause death were lower in the continuation group, but not statistically significantly: 0.50 (0.12, 2.12; p = 0.35) and 0.69 (0.24, 1.95; p = 0.48), respectively. The results were similar in competing risks analyses. Despite having characteristics associated with worse prognosis, women who continued HAART postpartum had lower hazard ratio point estimates for ADEs or death and non-ADEs or death than women who discontinued HAART. Larger studies with longer follow-up are indicated to assess this association.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055075476

Download citation: RISBibTeXText

PMID: 20438375

DOI: 10.1089/apc.2009.0283


Related references

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clinical Infectious Diseases 48(8): 1138-1151, 2009

Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy. Plos One 9(10): E111400, 2016

Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy. HIV Medicine 16(5): 265-272, 2015

Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. Journal of the International Aids Society 21(1), 2018

Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy. Aids 28(16): 2407-2415, 2015

Short Communication: HIV RNA Levels Predict AIDS-Defining and Non-AIDS-Defining Cancers After Antiretroviral Therapy Initiation Among HIV-Infected Adults. Aids Research and Human Retroviruses 31(5): 514-518, 2016

Immune restoration and onset of new AIDS-defining events with combination antiretroviral therapy in HIV type-1-infected immigrants in the Netherlands. Antiviral Therapy 15(6): 871-879, 2010

Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. Journal of Infectious Diseases 211(2): 178-186, 2015

Incidence and risk factors of non AIDS-defining as compared with AIDS-defining infections and cancers in a cohort of HIV-infected patients initiating a protease inhibitor -containing regimen. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 320, 2001

Maintaining Antiretroviral Therapy Reduces the Risk of Aids-Defining Events in Patients with Uncontrolled Viral Replication and Profound Immunodeficiency. Yearbook of Medicine 2008: 115-116, 2008

Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency. Clinical Infectious Diseases 46(2): 296-304, 2008

Incidence of AIDS-Defining Opportunistic Infections and Mortality during Antiretroviral Therapy in a Cohort of Adult HIV-Infected Individuals in Hanoi, 2007-2014. Plos One 11(3): E0150781, 2016

Decreasing incidence of CNS AIDS defining events associated with antiretroviral therapy. Neurology 55(9): 1424, 2000

Decreasing incidence of CNS AIDS-defining events associated with antiretroviral therapy. Neurology 54(9): 1856-1859, 2000

Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. Journal of Acquired Immune Deficiency Syndromes 51(5): 631-639, 2009